Trial | NCT04522830  Report issue

Title

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19
A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    28
Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
Study Started
Jul 30
2020
Primary Completion
Feb 28
2021
Study Completion
Feb 28
2021
Last Update
Apr 13
2021

Drug BTL-TML-COVID

Sublingual dosing of BTL-TML-COVID on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime. Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment. Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime. Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.

Drug Placebo

Sublingual dosing of matching placebo on days 1 and 2 - Day 1 - 1 drop every 15 minutes for the first hour of initiation of treatment then every hour for the balance of the day until bedtime. Day 2 - 1 drop every 2-3 hours for a total of 6 times during the day. The parallel group assignment will only be maintained until the completion of a minimum of 48 hours of blinded study drug dosing, at which point all subjects will receive the active treatment. Day 3 - 1 drop every 15 mins for the first hour of the day, then every hour for the balance of the day until bedtime. Days 4 through 10 - 1 drop every 3-4 hours for a total of four times during the day.

BTL-TML-COVID Experimental

BTL-TML-COVID

Placebo Placebo Comparator

Placebo

Criteria 

Inclusion Criteria:

40 years of age or older
Provide written informed consent
Have a SARS-COV-19 diagnostic test with positive results

Exclusion Criteria:

Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
Subjects currently hospitalized
Subjects who have received a COVID vaccination
Subjects with a diagnosis of immunodeficiency
No Results Posted